Skip to content

Clinical study on the prevention of recurrent bladder cancer after renal pelvis carcinoma operation

Clinical study on the prevention of recurrent bladder cancer after renal pelvis carcinoma operation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075362
Enrollment
Unknown
Registered
2023-09-01
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal pelvis carcinoma

Interventions

Sponsors

The First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Unilateral renal pelvis cancer, unilateral renal pelvis cancer combined with ureter cancer, unilateral renal pelvis cancer combined with bladder cancer (cystectomy) and unilateral renal pelvis cancer combined with ureter cancer and bladder cancer (cystectomy) were diagnosed at the time of initial diagnosis.Patients were between 30 and 80 years old; ? Open, laparoscopic or robot-assisted laparoscopic radical nephreterectomy + cystectomy;Open, laparoscopic or robot-assisted laparoscopic radical nephreterectomy + cystectomy +TURB should be performed for unilateral renal pelvis cancer combined with bladder cancer or unilateral renal pelvis cancer combined with ureteral cancer + bladder cancer, excluding partial cystectomy outside the ureteral opening. ?The postoperative pathological type was urothelial carcinoma, with clear pathological grades and stages, and a clear description of the tumor base, invasion depth and maximum cross section. ? Complete clinical data and follow-up data.

Exclusion criteria

Exclusion criteria: ? Bilateral renal pelvis carcinoma at the first diagnosis; ?Perioperative neoadjuvant chemoradiotherapy or targeted therapy; ?Postoperative pathological staging of tumor was incomplete or postoperative pathological diagnosis was other pathological types of non-urothelial carcinoma; ? Incomplete clinical data or lost follow-up during follow-up.

Design outcomes

Primary

MeasureTime frame
Recurrence rate of bladder tumor;Recurrence time of bladder tumor;Progression-free survival;Recurrence-free survival;Tumor-specific survival rate;Overall survival;

Countries

China

Contacts

Public ContactChuize Kong

The First Affiliated Hospital of China Medical University

kongchuize_cmu@sina.cn+86 136 0492 5361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026